Dernière mise à jour : 27 février 2020
Lisa Farrell, CADTH Liaison Officer, Nova Scotia, hosted an online overview session on biosimilars with the Canadian Hospital Pharmacists Association (CHPA). They discussed what biosimilars are, and how the regulatory, health technology assessment, and reimbursement pathway differs for them from other products
Marina Richardson, MSc, Clinical Research Manager at CADTH addressed some of the questions that patients, clinicians, and payers may have about these products, and Helen Mai, Policy and Strategy Analyst, Pharmaceutical Reviews at CADTH was also there to answer questions.
Dernière mise à jour : 27 février 2020